Outlook Therapeutics (OTLK) has released an update to notify the public and investors about an entry into a material definitive agreement.
Outlook Therapeutics, Inc. entered into agreements on January 22, 2024, to raise $60 million through a private placement of shares and warrants with institutional and accredited investors, and an additional $5 million in a separate agreement with Syntone. The agreements include conditions such as stockholder approval, a reverse stock split, and meeting Nasdaq listing requirements. Warrants come with exercise conditions and beneficial ownership limitations. The proceeds are primarily for clinical development and corporate purposes. Concurrently, the company amended a convertible note with Streeterville Capital, LLC, with terms including a conversion price adjustment and extended maturity date, contingent on a qualified offering and stockholder approval. Registration rights agreements were also signed to facilitate the resale of these securities.
For further insights into OTLK stock, check out TipRanks’ Stock Analysis page.
